Spots Global Cancer Trial Database for er positive breast cancer
Every month we try and update this database with for er positive breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Role of the Immune Environment in Response to Therapy in Breast Cancer | NCT05396612 | Breast Cancer ER Positive Bre... HER2-negative B... TNBC - Triple-N... | Collection of p... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | NCT05101564 | Breast Cancer HER2-negative B... ER Positive Bre... | Alpelisib Tamoxifen Zotatifin Fulvestrant | 18 Years - | Stanford University | |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | NCT06176261 | Breast Cancer Breast Cancer F... Metastatic Trip... ER Positive Bre... HER2-negative B... HER2 Negative B... ER-negative Bre... | Datopotamab Der... | 18 Years - | Dana-Farber Cancer Institute | |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | NCT06016738 | Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B... | Palazestrant Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Olema Pharmaceuticals, Inc. | |
| A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer | NCT00234403 | Breast Cancer | gefitinib and f... | 18 Years - | AstraZeneca | |
| Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy | NCT00661531 | Breast Cancer Cancer of the B... Neoplasms, Brea... | Estrace Anastrozole | 18 Years - | Georgetown University | |
| Fulvestrant + Neratinib In Breast Cancer | NCT04901299 | Stage IV (Metas... Metastatic Brea... ER Positive Bre... PR-Positive Bre... HER2-negative B... Invasive Breast... | NERATINIB FULVESTRANT | 18 Years - | Massachusetts General Hospital | |
| Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | NCT04886531 | Breast Cancer HER2-positive B... ER Positive Bre... PR-Positive Bre... | Neratinib Letrozole (L) o... Trastuzumab | 18 Years - | Hoosier Cancer Research Network | |
| Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | NCT05101564 | Breast Cancer HER2-negative B... ER Positive Bre... | Alpelisib Tamoxifen Zotatifin Fulvestrant | 18 Years - | Stanford University | |
| AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer | NCT01361945 | Breast Cancer Metastatic Brea... HER-2 Positive ... ER Positive Bre... | AUY922 | 18 Years - | Texas Tech University Health Sciences Center, El Paso | |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | NCT06016738 | Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B... | Palazestrant Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Olema Pharmaceuticals, Inc. | |
| Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | NCT05720260 | Premenopausal B... Metastatic Brea... ER Positive Bre... | Goserelin Fulvestrant Capivasertib Durvalumab | 20 Years - | National Taiwan University Hospital | |
| Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | NCT05101564 | Breast Cancer HER2-negative B... ER Positive Bre... | Alpelisib Tamoxifen Zotatifin Fulvestrant | 18 Years - | Stanford University | |
| Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | NCT04504331 | Breast Cancer HER2-negative B... ER Positive Bre... PR-Positive Bre... | Infigratinib Tamoxifen Omnipaque 350 Iopamidol Computed tomogr... | 18 Years - | Stanford University | |
| A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer | NCT00234403 | Breast Cancer | gefitinib and f... | 18 Years - | AstraZeneca | |
| PRE-I-SPY Phase I/Ib Oncology Platform Program | NCT05868226 | HER2-positive B... Metastatic Canc... Metastatic Brea... Metastatic HER2-positive M... HER2 Mutation-R... HER-2 Protein O... HER2-negative B... Triple Negative... HR Positive Hormone Recepto... Estrogen Recept... Progesterone Re... Hormone Recepto... Solid Tumor Solid Tumor, Ad... Solid Carcinoma HER2 Low Breast... HER2 Low Breast... ER Positive Bre... PR-positive Bre... | ALX148 Fam-Trastuzumab... Zanidatamab Tucatinib | 18 Years - | QuantumLeap Healthcare Collaborative |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
